Medical Research Center, Shengjing Hospital of China Medical University, Shenyang, China.
Key Laboratory of Research and Application of Animal Model for Environmental and Metabolic Diseases, Shenyang, China.
J Cell Mol Med. 2019 Oct;23(10):6708-6719. doi: 10.1111/jcmm.14549. Epub 2019 Jul 21.
Long non-coding RNA (LncRNA) MEG3 serves a regulatory role in the progression of several types of cancer, but the role of MEG3 in laryngeal cancer is still unknown. The aim of this study was to explore the regulatory role and mechanism of MEG3 in laryngeal cancer. MEG3 expression in 50 laryngeal cancer tissue samples was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The effects of MEG3 overexpression on laryngeal cancer cells were investigated in vitro and in vivo. The mechanism of competitive endogenous RNA (ceRNA) was validated through luciferase reporter assay, RT-qPCR and Western blotting. MEG3 was down-regulated in laryngeal cancer tissues, and the low MEG3 expression was associated with advanced clinical stage. Additionally, MEG3 overexpression inhibited the proliferation and induced the apoptosis of laryngeal cancer cells in vitro and in vivo. Particularly, MEG3 bound to miR-23a specifically and a reciprocal negative regulation existed between miR-23a and MEG3. Moreover, MEG3 up-regulated apoptotic protease activating factor-1 (APAF-1), a known miR-23a's target, thereby leading to the activation of caspase-9 and caspase-3. Meanwhile, these activated effects were rescued by miR-23a overexpression. In conclusion, the present study demonstrated that MEG3 functions as a novel tumour suppressive LncRNA in laryngeal cancer for the first time. Furthermore, MEG3 may act as a ceRNA to regulate APAF-1 expression by competitive binding to miR-23a, thereby regulating the progression of laryngeal cancer.
长链非编码 RNA(LncRNA)MEG3 在多种类型的癌症进展中发挥调节作用,但 MEG3 在喉癌中的作用尚不清楚。本研究旨在探讨 MEG3 在喉癌中的调节作用和机制。通过逆转录定量聚合酶链反应(RT-qPCR)检测 50 例喉癌组织样本中 MEG3 的表达。在体外和体内研究了 MEG3 过表达对喉癌细胞的影响。通过荧光素酶报告基因检测、RT-qPCR 和 Western blot 验证了竞争性内源性 RNA(ceRNA)的机制。MEG3 在喉癌组织中下调,低 MEG3 表达与晚期临床分期相关。此外,MEG3 过表达抑制了喉癌细胞在体外和体内的增殖,并诱导了其凋亡。特别是,MEG3 特异性结合 miR-23a,并且 miR-23a 和 MEG3 之间存在相互负调控关系。此外,MEG3 上调了凋亡蛋白酶激活因子-1(APAF-1),即已知的 miR-23a 的靶标,从而导致 caspase-9 和 caspase-3 的激活。同时,miR-23a 过表达挽救了这些激活作用。总之,本研究首次证明 MEG3 作为一种新型肿瘤抑制性 LncRNA 在喉癌中发挥作用。此外,MEG3 可能通过与 miR-23a 竞争结合作为 ceRNA 来调节 APAF-1 表达,从而调节喉癌的进展。